基于抗体的治疗药物的配方开发中的机会
Qingyan Hu1, Yunsong Frank Li2
1Formulation Development, Regeneron Pharmaceuticals, Tarrytown, NY 10591, United States.
Antibody therapeutics
|September 24, 2025
概括
药物配方正在随着新的抗体基础疗法而发展. 关键趋势包括高度产品,固定剂量组合和人工智能集成,以提高稳定性,疗效和患者安全.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
背景情况:
- 活性药物成分 (API) 通过配方转化为药物产品.
- 生物技术的进步和患者需求正在推动基于抗体的新疗法和组合的开发.
- 生物制剂,特别是抗体的配方环境正在迅速发展.
研究的目的:
- 为提供基于抗体的治疗方法的当前配方的概述.
- 突出新兴趋势和热门话题在抗体配方.
- 讨论创新技术和可持续实践在这个领域的重要性.
主要方法:
- 这是一篇社论,介绍了该领域的审查和讨论.
- 它综合了关于当前抗体治疗药物的配方策略的信息.
- 它确定并讨论了关键的新兴趋势和技术.
主要成果:
- 由于生物技术的进步和患者的特定需求,抗体配方领域正在扩大.
- 关键趋势包括高度配方,固定剂量组合,新型辅助剂,先进的输送技术和人工智能 (AI) 整合.
- 创新技术和可持续实践对于满足未来需求至关重要.
结论:
- 药物配方对于确保基于抗体的治疗方法的稳定性,可制造性,有效性和安全性至关重要.
- 抗体配方的演变对于推进患者护理和解决治疗挑战至关重要.
- 未来的进展将取决于配方技术和可持续制造方法的持续创新.
更多相关视频
04:24Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
Published on: June 16, 2023
2.3K
07:53Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
Published on: August 16, 2019
9.8K
相关概念视频
Hybridoma Technology
17.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.3K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Antibody Structure
65.3K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.3K
Antibody Actions
2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K
